Grant: Travel Awards - Institute Community Support
McGill University
$1,500.00
A longitudinal analysis of changes in a marker of liver fibrosis over time among NNRTI and PI users in the Canadian Co-infection Cohort Study
FY 2015-16
Summary
Since the introduction of combination antiretroviral therapy, persons living with HIV live longer. However, those who are co-infected with hepatitis C tend to develop liver diseases faster than those who are infected with HIV only. Because in most cases, HIV treatment is a lifelong therapy, it is essential to understand whether or not some regimens could be more harmful to the liver than others. We studied a cohort of HIV-hepatitis C co-infected persons from 17 clinical centres across Canada. These persons are followed over time, with study visits every six months. We compared rates of liver fibrosis progression for two types of regimens commonly used. We found that regimens containing a drug in the "protease inhibitor" class were associated with progression of liver fibrosis, but not regimens containing a drug in the "non-nucleoside reverse transcriptase inhibitor" class. These findings could have important implications in the selection of HIV treatment for HIV-hepatitis C co-infected persons to prevent the development of liver diseases.
Department
Program
Travel Awards - Institute Community Support
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331745
Name
Brunet Laurence
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
HIV/AIDS and/or other Sexually Transmitted and Blood-borne Infections (STBBIs).
Projecttitle
A longitudinal analysis of changes in a marker of liver fibrosis over time among NNRTI and PI users in the Canadian Co-infection Cohort Study
Programtype2
Undefined
Orgnameinp2
McGill University
Cihramount2
$1,500
Cihrequipment2
$0
Programname2
Travel Awards - Institute Community Support
Keyworddelim
Apri Score; Cohort Study; Combination Antiretroviral Therapy; Generalized Estimating Equations; Hepatitis C; Hiv; Liver Fibrosis; Non-Nucleoside Reverse Transcripor Inhibitors; Protease Inhibitors
Abstract
Since the introduction of combination antiretroviral therapy, persons living with HIV live longer. However, those who are co-infected with hepatitis C tend to develop liver diseases faster than those who are infected with HIV only. Because in most cases, HIV treatment is a lifelong therapy, it is essential to understand whether or not some regimens could be more harmful to the liver than others. We studied a cohort of HIV-hepatitis C co-infected persons from 17 clinical centres across Canada. These persons are followed over time, with study visits every six months. We compared rates of liver fibrosis progression for two types of regimens commonly used. We found that regimens containing a drug in the "protease inhibitor" class were associated with progression of liver fibrosis, but not regimens containing a drug in the "non-nucleoside reverse transcriptase inhibitor" class. These findings could have important implications in the selection of HIV treatment for HIV-hepatitis C co-infected persons to prevent the development of liver diseases.
Competitiondate
201505
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brunet, Laurence
Approvedterm
1 an 0 mois
Cihrcontribution2
HIV/AIDS~ $1,500~ $0~
